ZINZINO AB (PUBL): PRELIMINARY SALES REPORT FEBRUARY 2019

STRONG SALES GROWTH DURING FEBRUARY; ZINZINO BASED REVENUE INCREASED 21% AND THE TOTAL GROUP REVENUE WITH 18% COMPARED WITH THE PREVIOUS YEAR.

The revenue for Zinzino's sales markets increasing by 21% to SEK 50.1 (41.4) million. Higher share of internal production during the month meant that Faun Pharma's external sales decreased by 22% and amounted to SEK 2.9 (3.7) million. Overall, the Group increased revenues by 18% to SEK 53.0 (45.1) million compared with the previous year.

Accumulated revenues for January-February increased with 16% to 106,5 (91,9) MSEK compared with the previous year.

Revenues distributed as follows:

Regions, MSEK Febr-19 Febr-18 Change 2019 2018 Change
Nordic Countries 29.8 31.2 -4% 60.7 61.7 -2%
Baltic States 4.7 3.6 29% 9.0 7.3 23%
Rest of Europa 13.6 5.1 168% 26.6 9.4 182%
North America 2.0 1.5 29% 3.7 3.2 16%
Zinzino 50.1 41.4 21% 100.0 81.6 23%
Faun Pharma 2.9 3.7 -22% 6.5 10.3 -37%
Zinzino Group 53.0 45.1 18% 106,5 91.9 16%

  
For more information please contact:
Dag Bergheim Pettersen, CEO Zinzino, tel. +47 (0) 932 25 700 www.zinzino.se

Pictures for free publication:
Marcus Tollbom, tel. +46 (0) 70-190 03 12

Certified Adviser:
Erik Penser Bank Aktiebolag: +46 (0)8 463 83 00 Email: certifiedadviser@penser.se

Tags:

About Us

Zinzino AB (publ.) is a global Direct Sales company that markets and sells test-based nutrition, skincare and life-style products. Zinzino owns the research unit BioActive Foods AS and production unit Faun Pharma AS. Zinzino is based in Gothenburg, with additional offices in Finland, Latvia, Norway, USA, Australia, Hong Kong and Malaysia. Zinzino is a public company and its shares are listed on Nasdaq First North Premier Growth Market.

Subscribe

Documents & Links